Pharmesis International Ltd. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2018. The Group's revenue increased by RMB 1.0 million or 5.1% from RMB 18.3 million for second quarter 2017 to RMB 19.3 million for second quarter 2018. Profit from operations was RMB 789,000 against RMB 69,000 a year ago. Profit before tax was RMB 595,000 against loss of RMB 120,000 a year ago. Loss attributable to the equity holders of the company was RMB 77,000 or 0.3 cents per fully diluted share against RMB 406,000 or 1.8 cents per fully diluted share a year ago. Net cash flows from operating activities were RMB 1,748,000 against net cash used in operating activities of RMB 4,718,000 a year ago. For the six months, revenue was RMB 34,656,000 against RMB 33,696,000 a year ago. Profit from operations was RMB 2,010,000 against RMB 405,000 a year ago. Profit before tax was RMB 1,646,000 against RMB 59,000 a year ago. Profit attributable to the equity holders of the company was RMB 178,000 or 0.8 cents per fully diluted share against loss of RMB 883,000 or 3.8 cents per fully diluted share a year ago. Net cash flow from operating activities was RMB 3,375,000 against net cash used in operating activities of RMB 256,000 a year ago. Acquisition of property, plant and equipment was RMB 1,277,000 against RMB 971,000 a year ago.